C ardiac troponin T (cTnT) is a thin filament protein that participates in cardiac muscle contraction. Detection of cTnT in peripheral blood indicates cardiomyocyte injury, and cTnT is 1 of the preferred biochemical markers for diagnosis and prognosis of acute coronary syndromes. 1,2 This low molecular weight protein is released into the circulation not only after damage to myocytes but also after inflammation and trauma. 3, 4 The detection limit of the conventional assay for cTnT is ≈0.01 μg per liter, but studies have shown that cTnT levels below this limit differentiates individuals at high or low risk for future cardiovascular events or death. 5,6 A recently developed highly sensitive assay for cardiac troponin T (hs-cTnT) can detect hs-cTnT levels 10 times lower than conventional assays. 7 A population-based study of older Background-High levels of cardiac troponin T, measured by a highly sensitive assay (hs-cTnT), are strongly associated with incident coronary heart disease and heart failure. To date, no large-scale genome-wide association study of hs-cTnT has been reported. We sought to identify novel genetic variants that are associated with hs-cTnT levels.
adults reported that increased levels when compared with undetectable levels of hs-cTnT are associated with incident heart failure (HF) and cardiovascular mortality. 8 Moreover, in a population-based sample without coronary heart disease (CHD), hs-cTnT is a significant predictor of incident CHD, as well as overall mortality and HF. 9 Clinical Perspective on p 88 cTnT is encoded by the TNNT2 gene, and mutations in this gene account for ≈15% of familial hypertrophic cardiomyopathy, which is associated with high risk of sudden cardiac death. 10, 11 It is plausible that serum cTnT levels may be influenced by genetic variation in the TNNT2 and other genes. But to date no genome-wide association study (GWAS) of cTnT levels has been published. In this study, we sought to identify novel genetic variants that contribute to cTnT levels, which were measured by the new highly sensitive assay.
Methods

Study Populations
The Atherosclerosis Risk in Communities Study (ARIC) is a prospective cohort study designed to ascertain the cause and predictors of cardiovascular disease, which enrolled 15 792 middle-aged adults from 4 US communities from 1987 to 1989. The Cardiovascular Health Study (CHS) is a prospective observational cohort study designed to investigate cardiovascular disease in older adults, which enrolled 5201 individuals in the original cohort from 1989 through 1990, with further enrollment of a minority sample of 687 blacks from 1992 through 1993. Their detailed designs have been published elsewhere. 12, 13 Participants were excluded on the basis of the following factors: (1) if they had prevalent CHD or HF when hs-cTnT levels were measured; (2) if they were first-degree relatives of someone else in the study; (3) if there were sample handling errors or race or sex discrepancies between reported data and genotype data; and (4) or if they did not give consent for use of DNA information.
hs-cTnT Measurement
In ARIC, hs-cTnT levels were measured using visit 4 plasma samples from 1996 to 1998. In the CHS, hs-cTnT levels were measured at baseline from 1989 through 1990 and 1992 through 1993 for European Americans (EAs) and blacks recruited in the original cohort, and from 1992 through 1993 and 1994 through 1995 for blacks recruited in the minority cohort. Plasma samples were stored at −70°C to −80°C and thawed before testing. Hs-cTnT levels were measured with the Elecsys Troponin T high sensitive assay (Roche Diagnostics, Indianapolis, IN). The range of detection of this assay is from 0.003 to 10 µg/L. For CHS participants with >1 hs-cTnT measurement, we selected the first measurement.
Genotyping and Imputation
Autosomal single-nucleotide polymorphisms (SNPs) were genotyped using the Affymetrix 6.0 chip for ARIC and the Illumina 370CNV chip for CHS. Each study imputed their genotype data to the ≈2.5 million SNPs identified in HapMap CEU (Utah residents with ancestry from northern and western Europe) samples for EAs. For blacks, SNP data were imputed based on a panel of reference haplotypes using HapMap CEU and YRI (Yoruba in Ibadan, Nigeria) samples. MACH v1.0 in ARIC and BIMBAM v0.99 in CHS were used for the imputation, and allele dosage information was summarized in the imputation results. SNPs were excluded if they had no chromosomal location, were monomorphic, had a call rate <95%, or had a Hardy-Weinberg equilibrium P value <10 −6 for ARIC or P value <10 −5 for CHS. For each eligible SNP in both cohorts, the ratio of the observed versus expected variance of the dosage served as a measure of imputation quality. A ratio <0.3 was considered to be poor imputation quality, and these SNPs were removed from further analyses.
Statistical Analyses
Hs-cTnT levels were treated as a continuous and a dichotomous variable in 2 distinct regression analyses. In addition to genotype, covariates used in the regression were obtained at the time when hs-cTnT levels were measured. When analyzing continuous hs-cTnT levels, standard linear regressions were used. In EAs, the adjustment covariates were age, sex, and study site. In blacks, additional covariates included the first 10 principal components to account for population stratification. 14 Individuals whose cTnT levels were below the lowest detectable limit were assigned a value of 0.003 µg/L (the known detection limit of the assay). 7 All cTnT values were natural log-transformed before analysis. When analyzing dichotomized hs-cTnT levels, we used the recently recommended value of >99th percentile of hs-cTnT concentration to diagnose non-ST-elevation myocardial infarction. 7, 15 Therefore, we grouped hs-cTnT levels into 2 categories: <99th percentile versus ≥99th percentile and used logistic regression with this binary outcome. Because of the small number of blacks in the 2 cohorts with hs-cTnT levels ≥99th percentile, the logistic regression was applied only in EAs. The study-specific 99th percentile of hs-cTnT for ARIC and CHS is 0.027 µg/L and 0.036 µg/L, respectively.
In all analyses, the effects of SNPs were estimated under an additive genetic model; a locus with 2 copies of the coded alleles was coded as 2, the heterozygote was coded as 1, and 2 copies of the noncoded alleles were coded as 0. For each model and after genomic control adjustment, inverse variance fixed-effect meta-analyses were used to combine the results of the 2 cohorts within race strata and then again to meta-analyze the race-specific results to obtain an overall β coefficient, SE, and P value. Because of the relative small sample size of blacks, analyses with low minor allele frequency (MAF) would be underpowered or lead to spurious associations. Thus, SNPs with a MAF <1% for EAs and <10% for blacks, or absolute value of β coefficient >5, were excluded before the meta-analyses. Only SNPs present in both cohorts and race strata were included in the meta-analysis results. Quantile-quantile plots of the observed and expected P values for all eligible SNPs were generated for each analysis to illustrate the behavior of the test statistics. Genome-wide significance was defined as an overall P value <5×10 −8 in this study, and a P value <1×10 −5 was regarded as suggestive evidence for association. If >1 suggestive or significant SNP clustered at a genetic locus, the SNP with the smallest P value was reported as the locus's sentinel marker. Forest plots showing cohort/race-specific findings and regional plots showing linkage disequilibrium and gene information were generated for genome-wide significant SNPs in each analytic model. All analyses in CHS were performed by R (www.r-project.org) and by ProbABEL 16 in ARIC. Meta-analyses were performed by METAL (http://genome.sph.umich. edu/wiki/METAL_Program). The estimated post hoc power based on the parameter estimates presented here are: (1) for the linear model: 85% power with 12 000 individuals, MAF=0.48, α=5×10 −8 , and 0.35% variation explained by the SNP; and (2) binary model: 70% power with 10 000 individuals, MAF=0.2, α=5×10 −8 , and odds ratio=2.5.
Because hs-cTnT levels are known to have a skewed distribution, we analyzed the association of the top-ranking SNP in the linear model with categorical hs-cTnT levels using proportional odds logistic regression. 8, 9 We grouped the undetectable cTnT levels as the reference group, and the remaining participants were divided into approximate fourths (0.003-0.0055 µg/L, 0.0056-0.0085 µg/L, 0.0086-0.0135 µg/L, and >0.0135 µg/L). The proportional odds assumption was tested using the Brant test and the same strategy was applied for the meta-analysis as described above. These analyses were performed using Stata (StataCorp, www.stata.com) and R (www.r-project.org).
Association with HF and CHD
The association between the genome-wide significant SNPs in each model and incident HF were tested in ARIC using a Cox proportional hazards model adjusted for age, sex, and study site. The analyses were performed by R (www.r-project.org). In ARIC, the diagnosis of HF was based on International Classification of Diseases, Ninth Revision code 428.3, whereas incident HF was defined as the first hospitalization or death from HF for those without a prior HF hospitalization.
Individuals were followed up for events through December 31, 2008; those who were lost to follow-up were censored at the date of last contact. The association between the genome-wide significant SNPs and CHD were examined from results in 22 233 cases and 64 762 controls from the Coronary Artery Disease Genome-Wide Replication And Meta-Analysis (CARDIoGRAM) Study. 17, 18 Although details differed among the contributing studies in CARDIoGRAM, the definition of CHD included clinically defined myocardial infarction or angiographically accessed coronary artery disease. Information about the CARDIoGRAM study is provided in online-only Data Supplement A.
Results
A total of 9491 EAs and 2053 blacks were included in these genome-wide association analyses. The characteristics of 11 544 study participants free of CHD and HF at the time hs-cTnT levels were measured are shown in the Table. The average age at baseline varied from 61.68 to 72.82 years, and women were the majority in each cohort. By design, CHS study participants were older than those in ARIC. The mean hs-cTnT levels and the proportion of hs-cTnT levels below the detectable limit were similar across race strata and cohorts. Both EAs and blacks had average body mass indices >25, and blacks tended to have higher prevalence of hypertension and diabetes mellitus.
Linear Model and Proportional Odds Logistic Model
For the analyses of hs-cTnT as a continuous variable, the race-and-cohort-specific genomic control parameters were 1.03 for ARIC EAs, 1.03 for ARIC blacks, 1.02 for CHS EAs, and 1.05 for CHS blacks. After doing the 2-stage metaanalyses, 2 SNPs exceeded the genome-wide significance threshold (P<5×10 −8 ). The overall genomic control parameter of 1.0 for this model suggested negligible population stratification. The Manhattan plot and quantile-quantile plot of the 2-stage meta-analyzed P values are shown in Figure 1 . Twelve genetic loci were identified with genome-wide suggestive evidence for association (P<1×10 −5 ). These suggestive loci, presented in online-only Data Supplement B, are not discussed further.
The 2 genome-wide significant SNPs were rs10091374 (P=9.06×10 −9 ) and rs6989313 (P=2.33×10 −8 ) located at chromosome 8q13. These 2 SNPs were in strong linkage disequilibrium, r 2 ≥0.8. The top SNP, rs10091374, was an imputed SNP with MAF=0.483 and estimated effect size β=−0.04 (T→A), corresponding to a ≈4% reduction in hs-cTnT level per additional A allele. This SNP lies between 2 genes; it is 70.9 kb from NCOA2 (nuclear receptor coactivator 2) and 98.5 kb from TRAM1 (translocation associated membrane protein 1). A forest plot of the 2-stage meta-analysis result for rs10091374 is shown in Figure 2 , and information about linkage disequilibrium and other SNPs in this region are presented in online-only Data Supplement Supplement B.
We further conducted proportional odds logistic regression for rs10091374, and per additional A allele for rs10091374, the odds of being in the 4 higher hs-cTnT categories versus the undetectable hs-cTnT category were reduced by 11% (odds ratio=0.89; P=4.5×10 −6 ). In the Atherosclerosis Risk in Communities Study (ARIC), prevalent hypertension included use of antihypertensive medication or measured blood pressure (systolic blood pressure ≥140 mm Hg, diastolic blood pressure ≥90 mm Hg); prevalent diabetes mellitus was defined as fasting glucose levels ≥126 mg/dL, nonfasting glucose levels ≥200 mg/dL, or self-reported diagnosis of diabetes mellitus or use of diabetic medication. In the Cardiovascular Health Study (CHS), prevalent hypertension included measured blood pressure (systolic blood pressure ≥140 mm Hg, diastolic blood pressure ≥90 mm Hg) or use of antihypertensive drug and reports of physician diagnosis of hypertension; prevalent diabetes mellitus was defined as fasting glucose levels ≥126 mg/dL, or use of insulin or an oral hypoglycemic drug. B indicates blacks.; EA, European Americans; and hs-cTnT, highly sensitive cardiac troponin T.
*hs-cTnT levels, median (quartile 1, quartile 3). For continuous variables, mean values±SEs are shown. Categorical variables are given as percentage.
Logistic Model
In the dichotomized analyses of hs-cTnT for EAs, the genomic control parameters were 1.01 for ARIC, 1.06 for CHS, and 1.0 after the meta-analysis. One SNP, rs12564445, reached the genome-wide significance threshold (odds ratio=2.33; G→A; P=4.73×10 −8 ; MAF=0.197). This SNP was imputed in ARIC and CHS EAs. rs12564445 is located in an intron of the gene that codes for cTnT type 2 (TNNT2) and is responsible for 133% greater odds of being in the 99th percentile group for each additional A allele. Information about linkage disequilibrium and other SNPs in this region is presented in Figure 3 . In addition to this region, 8 more regions were identified with suggestive evidence for genome-wide association (P<1×10 −5 
Association With HF and CHD
We next analyzed the association of rs10091374 and rs12564445 with 1119 incident HF events in ARIC EAs and with 22 233 CHD cases from the CARDIoGRAM consortium. 17, 18 In all cases except 1, the results were not statistically significant (data not shown; P>0.05). rs12564445 was significantly associated with incident HF among 8894 ARIC EAs with an average 18 years follow-up time (hazard ratio=1.16; 95% confidence interval, 1.05-1.28; P=0.004). We repeated the analyses with a competing risk model developed by Fine and Grey, 19 and the results were very similar to the Cox regression reported here, subhazard ratio was 1.17 (95% confidence interval, 1.06-1.30; P=0.002).
Discussion
This study evaluated the association between genetic variants and hs-cTnT levels among participants free of CHD and HF. The meta-analysis, which included 9491 EAs and 2053 blacks, identified 1 locus on chromosome 8q13 that was significantly associated with hs-cTnT levels and 12 additional suggestive loci. Furthermore, 1 locus, TNNT2, was associated with high hs-cTnT levels (≥99th percentile) in 9491 EAs together with 8 additional loci showing suggestive association. The effects of both SNPs on quantitative and categorical hs-cTnT levels are generally consistent. For rs10091374, the direction of effect is the same in all 4 analyses (2 race groups × 2 phenotype definitions). There is ≈21% lower odds of being in the 99th percentile of hs-cTnT per additional A allele, which is consistent with the A allele lowering hs-cTnT levels. For rs12564445, the effect is consistent in blacks but not in EAs. It is possible that the significant association of rs12564445 with elevated hs-cTnT levels represents the biological effect of a low frequency variant private to EAs.
The gene most likely responsible for the association between hs-cTnT levels and chromosome 8q13 is NCOA2, which encodes a transcriptional coregulatory protein that aids in the function of nuclear hormone receptors. Our observation that an additional A allele at this locus decreases hs-cTnT levels was confirmed by proportional odds logistic regression. Overexpression of NCOA2 has been detected in both proliferating and confluent myoblasts, and Western blot analysis shows that it increases during myogenesis, 20 and reduced expression has been observed in pulmonary arterial hypertension. 21 Thus, NCOA2 may play a role in promoting muscle cells maintenance and growth, eventually influencing cTnT levels.
In addition, we hypothesize that specific genes may contribute to high hs-cTnT levels (≥99th percentile in the population). Under such a model, rs12564445 in the TNNT2 gene reached the genome-wide significance threshold in our analysis. TNNT2 encodes cTnT, and it is well known that mutations in this gene can cause familial hypertrophic cardiomyopathy, [22] [23] [24] familial dilated cardiomyopathy, [25] [26] [27] and left ventricular noncompaction. 28 The specificity of hs-cTnT assay for categorizing non-ST-elevation myocardial infarction is ≈80%. 7 Given the function of TNNT2, it would be interesting to explore whether variation in TNNT2 contributes to the remaining ≈20% false-positives.
Several recent epidemiological studies have reported that hs-cTnT levels predict incident HF and CHD in multiple populations. 8, 9, 29 In this GWAS, 2 loci reached genome-wide significance, but only rs12564445 was significantly associated with incident HF in EAs, and neither of them was significantly associated with CHD. In previous studies, mutations in TNNT2 have been associated with hypertrophic cardiomyopathy, [21] [22] [23] and in ARIC this variant is associated with ECG-determined left ventricular hypertrophy (data not shown). In this study, TNNT2 gene variation is related to both hs-cTnT levels and incident HF, and it has been repeatedly reported that hs-cTnT levels are associated with incident HF. It is likely that TNNT2 alters the levels of hs-cTnT, which subsequently influences the onset of HF. But such relations were not found for incident CHD. Given these results, we suggest that hs-cTnT may not be in the causal pathway for CHD but may in some cases be in the causal pathway for HF.
Strengths and Limitations
This study is the first GWAS to reveal genetic risk variants for hs-cTnT levels. The effect size and MAF of the genetic variant detected in the linear model were consistent across EAs and blacks, which provides some evidence that the genetic mechanism for hs-cTnT may be similar between the 2 groups. Our study also has several limitations. A study in CHS indicated that the changes of hs-cTnT levels over time were associated with HF, 8 but hs-cTnT levels were only measured at 1 visit in ARIC. Thus, we were unable to comment on the genetic contribution to the variability of hs-cTnT levels. Different thresholds for hs-cTnT based on 99th study-specific percentiles were used in the current study. We hypothesized that genetic variation contributes to high hs-cTnT levels, but discovered that the 99th percentile of 0.014 µg/L provided by the manufacturer is based on healthy people who are ≈10 and 20 years younger than ARIC and CHS, respectively. 30 Because of the increased age of CHS and ARIC participants, the distribution of hs-cTnT was shifted up in both studies. Thus, we analyzed a study-specific 99th percentile threshold, which could complicate future replication studies. For blacks, we could not examine genetic association with extremely high hs-cTnT levels due to limitations of the available sample size. Although the sensitivity of this new cTnT assay is improved, there still is a lowest detectable limit, and those with missing data at baseline were imputed with this low value limit as a proxy for an undetectably low true value. If this low value were due to genetic variation, the limitations of the assay may impact the statistical power of these analyses. Finally, the effect of the significant SNP observed under the linear model was interpreted in the context of the nearest gene, but it is possible that the true casual variant may be located in another gene or in an intergenic region.
Conclusions
We identified 2 loci that reached genome-wide significance from a GWAS of hs-cTnT in 2 prospective cohort studies: ARIC and CHS. One SNP, rs10091374, near NCOA2 on chromosome 8q13 was significantly associated with quantitative hs-cTnT levels in EAs and blacks. The other SNP, rs12564445, in TNNT2 on chromosome 1q32 was significantly related to high levels of hs-cTnT in EAs. These results contribute to the knowledge base of cTnT physiology and to our understanding of its role as a biomarker of cardiac injury. Further use of the new assay should enable replication of these results.
